STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

Darnell, 2002, Transcription factors as targets for cancer therapy, Nat Rev Cancer, 2, 740, 10.1038/nrc906

Darnell, 1997, STATs and gene regulation, Science, 277, 1630, 10.1126/science.277.5332.1630

Bromberg, 2000, The role of STATs in transcriptional control and their impact on cellular function, Oncogene, 19, 2468, 10.1038/sj.onc.1203476

Ihle, 1996, STATs: signal transducers and activators of transcription, Cell, 84, 331, 10.1016/S0092-8674(00)81277-5

Herrington, 2000, The role of STAT proteins in growth hormone signaling, Oncogene, 19, 2585, 10.1038/sj.onc.1203526

Alvarez, 2006, Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor, Cancer Res, 66, 3162, 10.1158/0008-5472.CAN-05-3757

Yin, 2006, Active Stat3 is required for survival of human squamous cell carcimoma cells in serum-free conditions, Mol Cancer, 5, 15, 10.1186/1476-4598-5-15

Kusaba, 2006, Activation of STAT3 is a marker of poor prognosis in human colorectal cancer, Oncol Rep, 15, 1445

Morikawa, 2011, STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers, Clin Cancer Res, 17, 1452, 10.1158/1078-0432.CCR-10-2694

de la Iglesia, 2008, Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness, J Neurosci, 28, 5870, 10.1523/JNEUROSCI.5385-07.2008

de la Iglesia, 2008, Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway, Genes Dev, 22, 449, 10.1101/gad.1606508

Copeland, 1995, Distribution of the mammalian Stat gene family in mouse chromosomes, Genomics, 29, 225, 10.1006/geno.1995.1235

Lai, 2010, Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches, Drug Resist Updat, 13, 67, 10.1016/j.drup.2010.04.001

Quesnelle, 2007, STAT-mediated EGFR signaling in cancer, J Cell Biochem, 102, 311, 10.1002/jcb.21475

Gao, 2005, Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo, Clin Cancer Res, 11, 6333, 10.1158/1078-0432.CCR-05-0148

Kisseleva, 2002, Sigaling through the JAK-STAT pathway, recent advances and future challenges, Gene, 285, 1, 10.1016/S0378-1119(02)00398-0

Aggarwal, 2009, Signal tansducer and activator of transcription-3, inflammation, and cancer, Ann NY Acad Sci, 1171, 59, 10.1111/j.1749-6632.2009.04911.x

Pawson, 2001, SH2 domains, interaction modules and cellular wiring, Trends Cell Biol, 11, 504, 10.1016/S0962-8924(01)02154-7

Zhong, 1994, Stat3, a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6, Science, 264, 95, 10.1126/science.8140422

Leeman, 2006, STAT3 as a therapeutic target in head and neck cancer, Expert Opin Biol Ther, 6, 231, 10.1517/14712598.6.3.231

Takeda, 1997, Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality, Proc Natl Acad Sci USA, 94, 3801, 10.1073/pnas.94.8.3801

Yang, 2007, STAT3 regulates cytokine-mediated generation of inflammatory helper T cells, J Biol Chem, 282, 9358, 10.1074/jbc.C600321200

Miyoshi, 2011, Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor, J Invest Dermatol, 131, 108, 10.1038/jid.2010.255

Zhang, 2011, Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells, Am J Physiol Gastrointest Liver Physiol, 300, G454, 10.1152/ajpgi.00458.2010

Mora, 2002, Constitutive activation of Atat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells, Cancer Res, 62, 6659

Burger, 2009, Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo, Mol Cancer Ther, 8, 26, 10.1158/1535-7163.MCT-08-0149

Wei, 2003, Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway, Oncogene, 22, 1517, 10.1038/sj.onc.1206226

Lopiccolo, 2008, Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations, Drug Resist Updat, 11, 32, 10.1016/j.drup.2007.11.003

Sasse, 1997, Mutational analysis of acute-phase response factor/Stat3 activation and dimerization, Mol Cell Biol, 17, 4677, 10.1128/MCB.17.8.4677

Shuai, 1994, Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions, Cell, 76, 821, 10.1016/0092-8674(94)90357-3

Fletcher, 2008, Mild, efficient and rapid O-debenzylation of ortho-substituted phenols with trifluoroacetic acid, Tetrahedron Lett, 49, 4817, 10.1016/j.tetlet.2008.06.022

Yu, 1995, Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein, Science, 269, 81, 10.1126/science.7541555

Smithgall, 2000, Control of myeloid differentiation and survial by Stats, Oncogene, 19, 2612, 10.1038/sj.onc.1203477

Bowman, 2000, STATs in oncogenesis, Oncogene, 19, 2474, 10.1038/sj.onc.1203527

Catlett-Falcone, 1999, STAT proteins as novel targets for cancer therapy, Curr Opin Oncol, 11, 490, 10.1097/00001622-199911000-00010

Inamura, 2005, Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines, Biochim Biophys Acta, 1745, 401, 10.1016/j.bbamcr.2005.06.003

Yang, 2010, Mechanism of the synergistic antiproliferative effect of gefitinib and interferon-alpha in sarcoma cell lines, Proc 101st Ann Meet AACR, 398–399

Turkson, 2000, STAT proteins: novel molecular targets for cancer drug discovery, Oncogene, 19, 6613, 10.1038/sj.onc.1204086

Yu, 2004, The STATs of cancer - new molecular targets come of age, Nat Rev Cancer, 4, 97, 10.1038/nrc1275

Aggarwal, 2006, Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer, Ann NY Acad Sci, 1091, 151, 10.1196/annals.1378.063

Jaganathan, 2011, A functional nuclear epidermal growth factor receptor, Src and Stat3 heteromeric complex in pancreatic cancer cells, PLoS One, 6, e19605, 10.1371/journal.pone.0019605

Arany, 2003, Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck, Cancer Lett, 199, 83, 10.1016/S0304-3835(03)00345-8

Masuda, 2002, Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma, Cancer Res, 62, 3351

Chun, 2011, The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin, Mol Carcinog, 50, 439, 10.1002/mc.20728

Grandis, 2000, Contitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo, Proc Natl Acad Sci USA, 97, 4227, 10.1073/pnas.97.8.4227

Kijima, 2002, STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo, Cell Growth Differ, 13, 355

Huang, 2000, Constitutive activation of Stat 3 oncogene product in human ovarian carcinoma cells, Gynecol Oncol, 79, 67, 10.1006/gyno.2000.5931

Niu, 2002, Roles of activated Src and Stat3 signaling in melanoma tumor cell growth, Oncogene, 21, 7001, 10.1038/sj.onc.1205859

Chen, 2007, Stat3 activation in human endometrial and cervical cancers, Br J Cancer, 96, 591, 10.1038/sj.bjc.6603597

Van der Fits, 2010, MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary Syndrome, J Invest Dermatol, 131, 762, 10.1038/jid.2010.349

Loffler, 2007, Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer, Blood, 110, 1330, 10.1182/blood-2007-03-081133

Ahluwalia, 2011, Importins are critical for colorectal cancer (CRC) growth a nd are novel biomarkers of CRC. Underlying mechanisms include: increased nuclear transport of P-CREB and p-STAT3, VEGF gene promoter activation and aberrant VEGF expression, Gastroenterology, 140, S184, 10.1016/S0016-5085(11)60743-9

Wei, 2003, Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis, Oncogene, 22, 319, 10.1038/sj.onc.1206122

Xu, 2005, Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways, Oncogene, 24, 5552, 10.1038/sj.onc.1208719

Xie, 2004, Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis, Oncogene, 23, 3550, 10.1038/sj.onc.1207383

Dechow, 2004, Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C, Proc Natl Acad Sci USA, 101, 10602, 10.1073/pnas.0404100101

Yu, 2007, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Immunology, 7, 41

Kortylewski, 2005, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity, Nat Med, 11, 1314, 10.1038/nm1325

Kortylewski, 2008, Role of Stat3 in suppressing anti-tumor immunity, Curr Opin Immunol, 20, 228, 10.1016/j.coi.2008.03.010

Wang, 2004, Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells, Nat Med, 10, 48, 10.1038/nm976

Garcia, 2001, Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20, 2499, 10.1038/sj.onc.1204349

Nagpal, 2002, Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis, Cancer, 94, 2393, 10.1002/cncr.10499

Deng, 2010, STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer, World J Gastroenterol, 16, 5380, 10.3748/wjg.v16.i42.5380

Watson, 1995, Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts, Br J Cancer, 71, 840, 10.1038/bjc.1995.162

Kosaka, 2011, Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer, J Biomed Biotechnol, 2011, 1, 10.1155/2011/165214

Himpe, 2009, Insulin-like growth factor-I receptor signal transduction and the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway, Biofactors, 35, 76, 10.1002/biof.20

Sporeno, 1996, Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells, Blood, 87, 4510, 10.1182/blood.V87.11.4510.bloodjournal87114510

Demartis, 1996, Interleukin 6 receptor superantagonists are potent inducers of human multiple, Cancer Res, 56, 4213

Catlett-Falcone, 1999, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, 10, 105, 10.1016/S1074-7613(00)80011-4

Johnson, 2005, Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells, Clin Cancer Res, 11, 6924, 10.1158/1078-0432.CCR-05-0757

Perry, 2004, TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3, Oncogene, 23, 8908, 10.1038/sj.onc.1208149

Gu, 2011, Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease, Biochimie, 93, 909, 10.1016/j.biochi.2011.02.009

Ulane, 2005, Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain, J Virol, 79, 10180, 10.1128/JVI.79.16.10180-10189.2005

Lesina, 2011, Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic Cancer, Cancer Cell, 19, 456, 10.1016/j.ccr.2011.03.009

Lindemann, 2011, SOCS3 promoter methylation methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation, Acta Neuropathol, 122, 241, 10.1007/s00401-011-0832-0

Kluge, 2011, Protein inhibitor of activated STAT3 expression in lung cancer, Mol Oncol, 5, 256, 10.1016/j.molonc.2011.03.004

Migone, 1998, Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 recepto; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells, Proc Natl Acad Sci USA, 95, 3845, 10.1073/pnas.95.7.3845

Schaper, 1998, Activation of the protein tyrosine phosphatease SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine Jak1 and limits acute-phase protein expression, Biochem J, 355, 557, 10.1042/bj3350557

Irie-Sasaki, 2001, CD45 is a JAK phosphatase and negatively regulates cytokine recptor signalling, Nature, 409, 349, 10.1038/35053086

Sun, 2002, PTEN is a negative regualtor of STAT3 activation in human papillomavirus-infected cells, J Gen Virol, 83, 1651, 10.1099/0022-1317-83-7-1651

Desrivières, 2006, The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition, J Mammary Gland Biol Neoplasia, 11, 75, 10.1007/s10911-006-9014-4

Scoles, 2002, Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT singling, Hum Mol Genet, 11, 3179, 10.1093/hmg/11.25.3179

Bhasin, 2008, Design, synthesis, and studies of small molecule STAT3 inhibitors, Bioorg Med Chem Lett, 18, 391, 10.1016/j.bmcl.2007.10.031

Esquela-Kerscher, 2006, Oncomirs - microRNAs with a role in cancer, Nat Rev Cancer, 6, 259, 10.1038/nrc1840

Akao, 2006, let-7 MicroRNA functions as a potential grwoth suppressor in human colon cancer cells, Biol Pharm Bull, 29, 903, 10.1248/bpb.29.903

Chan, 2005, MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells, Cancer Res, 65, 6029, 10.1158/0008-5472.CAN-05-0137

Takamizawa, 2004, Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival, Cancer Res, 64, 3753, 10.1158/0008-5472.CAN-04-0637

Yanaihara, 2006, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025

Johnson, 2005, RAS is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014

He, 2005, A microRNA polycistron as a potential human oncogene, Nature, 435, 828, 10.1038/nature03552

Foshay, 2009, miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation, Dev Biol, 326, 431, 10.1016/j.ydbio.2008.11.016

Krichevsky, 2006, Specific microRNAs modulate embryonic stem cell-derived neurogenesis, Stem Cells, 24, 857, 10.1634/stemcells.2005-0441

Meng, 2007, The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes, J Biol Chem, 282, 8256, 10.1074/jbc.M607712200

Niu, 1999, Gene therapy with dominant-negative Stat3 suprresses growth of the murine melanoma B16 tumor in vivo, Cancer Res, 59, 5059

Niu, 2001, Overexpression of a dominant-negative signal transducer and activator of trnascription 3 varian in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest, Cancer Res, 61, 3276

Mishra, 2009, MicroRNA reexpression as differentiation therapy in cancer, J Clin Invest, 119, 2119

Liang, 2011, Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo, Asian J Androl, 13, 481, 10.1038/aja.2010.167

Petrocca, 2011, Promise and chanllenge of RNA interference-based therapy for cancer, J Clin Oncol, 29, 747, 10.1200/JCO.2009.27.6287

Fletcher, 2009, Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein, Biochem Cell Biol, 87, 825, 10.1139/O09-044

Turkson, 2001, Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation, J Biol Chem, 276, 45443, 10.1074/jbc.M107527200

Turkson, 2004, Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity, Mol Cancer Ther, 3, 261, 10.1158/1535-7163.261.3.3

Siddiquee, 2007, Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity, Proc Natl Acad Sci USA, 104, 7391, 10.1073/pnas.0609757104

Lin, 2009, The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling, Oncogene, 28, 961, 10.1038/onc.2008.448

Hayakawa, 2010, A novel direct STAT3 inhibitor OPB-31121 induces tumor-specific growth inhibition in a wide4 range of hematopoietic malignacies and effectively suppresses the chemotherapy resistant quiescent cell in vivo, 52nd ASH Ann Meet & Expo III-56

Lo, 2008, Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and akylators, Clin Cancer Res, 14, 6042, 10.1158/1078-0432.CCR-07-4923

Real, 2002, Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells, Oncogene, 21, 7611, 10.1038/sj.onc.1206004

Oh, 2010, A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors, J Clin Oncol, 28, e13056, 10.1200/jco.2010.28.15_suppl.e13056

Sartor, 1997, Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells, Cancer Res, 57, 978

Garcia, 1997, Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells, Cell Growth Differ, 8, 1267

Song, 2003, Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells, Oncogene, 22, 4150, 10.1038/sj.onc.1206479

Haura, 2005, Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer, Clin Cancer Res, 11, 8288, 10.1158/1078-0432.CCR-05-0827

Gao, 2007, Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas, J Clin Invest, 117, 3846, 10.1172/JCI31871

Pfeiffer, 2009, Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer, Br J Cancer, 100, 1949, 10.1038/sj.bjc.6605068

Quintanilla-Martinez, 2003, Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma, Stat3 activation and cyclin D1 dysregulation are mutually exclusive events, Am J Pathol, 162, 1449, 10.1016/S0002-9440(10)64278-2

Chen, 2007, Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells, BMC Cancer, 7, 111, 10.1186/1471-2407-7-111

Grandis, 1998, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro, J Clin Invest, 102, 1385, 10.1172/JCI3785

Grandis, 2000, Epidermal growth factor receptor-mediated Stat3 singaling blocks apoptosis in head and neck cancer, Laryngoscope, 110, 868, 10.1097/00005537-200005000-00016

Sriuranpong, 2003, Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcimoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130, Cancer Res, 63, 2948

Ni, 2000, Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells, Cancer Res, 60, 1225

Barton, 2001, IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells, BMC Cancer, 1, 19, 10.1186/1471-2407-1-19

DeMiguel, 2002, Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice, Prostate, 52, 123, 10.1002/pros.10110

Barton, 2004, Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines, Mol Cancer Ther, 3, 11, 10.1186/1476-4598-3-11

Sanchez, 2003, STAT-3 activity in chemically-induced hepatocellular carcinoma, Eur J Cancer, 39, 2093, 10.1016/S0959-8049(03)00393-9

Dhir, 2002, Stat3 activation in prostatic carcinomas, Prostate, 51, 241, 10.1002/pros.10079

Sachez-Ceja, 2006, Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma, Lung Cancer, 54, 163, 10.1016/j.lungcan.2006.07.012

David, 2011, Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis, J Exp Clin Cancer Res, 30, 56, 10.1186/1756-9966-30-56

Niu, 2002, Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis, Oncogene, 21, 2000, 10.1038/sj.onc.1205260

Gritsko, 2006, Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells, Clin Cancer Res, 12, 11, 10.1158/1078-0432.CCR-04-1752

Gao, 2010, Inhibition of STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity, and induces mitochondria-dependent apoptosis in glioma cells, Intl J Radiat Oncol Biol Phys, 77, 1223, 10.1016/j.ijrobp.2009.12.036

Song, 2005, A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells, Proc Natl Acad Sci USA, 102, 4700, 10.1073/pnas.0409894102

Fuh, 2009, LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model, Br J Cancer, 100, 106, 10.1038/sj.bjc.6604793

Schust, 2006, Stattic: a small-molecule inhibitor of STAT3 activation and dimerization, Chem Biol, 13, 1235, 10.1016/j.chembiol.2006.09.018

Zhang, 2010, A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes, Biochem Pharmacol, 79, 1398, 10.1016/j.bcp.2010.01.001

Fletcher, 2009, Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities, Chem Biol Chem, 10, 1959, 10.1002/cbic.200900172

Siddiquee, 2007, An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and incuces antitumor cell effects, ACS Chem Biol, 2, 787, 10.1021/cb7001973

Uehara, 2009, Novel high-throughput screening system for identifying STAT3-SH2 antagonists, Biochem Biophys Res Commun, 380, 627, 10.1016/j.bbrc.2009.01.137

Ball, 2011, The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells, PLoS One, 6, e18820, 10.1371/journal.pone.0018820

Lin, 2010, A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activites and exhibits potent growth-suppressive activity in human cancer cells, Neoplasia, 12, 39, 10.1593/neo.91196

Matsuno, 2010, Identification of a new series of STAT3 inhibitors by virtual screening, ACS Med Chem Lett, 1, 371, 10.1021/ml1000273

Ashizawa, 2011, Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation, Int J Oncol, 38, 1245